Enlivex Doses First Patient in COVID-19 Trial
Ticker: ENLV · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, covid-19, drug-development
Related Tickers: ENLX
TL;DR
Enlivex dosed first patient in Phase II COVID-19 trial with Allocetra.
AI Summary
On June 24, 2024, Enlivex Therapeutics Ltd. announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase II clinical trial for its drug candidate, Allocetra, for the treatment of severe COVID-19. This trial is being conducted at Hadassah Medical Center in Israel.
Why It Matters
This marks a significant step in the clinical development of Allocetra for a serious condition, potentially offering a new treatment option if successful.
Risk Assessment
Risk Level: medium — Clinical trials are inherently risky, and the success of Allocetra in treating severe COVID-19 is not guaranteed.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra (drug_candidate) — Drug being tested
- June 24, 2024 (date) — Date of announcement
- Hadassah Medical Center (company) — Clinical trial site
FAQ
What is the purpose of the Phase II clinical trial announced by Enlivex?
The trial is investigating the efficacy of Allocetra in treating severe COVID-19.
Who is initiating and conducting the clinical trial?
The trial is investigator-initiated and randomized, placebo-controlled, and conducted at Hadassah Medical Center.
When was the announcement made regarding the dosing of the first patient?
The announcement was made on June 24, 2024.
What is the name of the drug candidate being tested?
The drug candidate being tested is Allocetra.
What type of trial is this, and what is the condition being studied?
It is a Phase II, investigator-initiated, randomized, placebo-controlled trial for severe COVID-19.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-06-24 08:02:17
Filing Documents
- ea020830901-6k_enlivex.htm (6-K) — 9KB
- ea020830901ex99-1_enlivex.htm (EX-99.1) — 12KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-054992.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: June 24, 2024 2